• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Definium Therapeutics, Inc. - Common Shares (NQ:DFTX)

    45.26 +2.63 (+6.17%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 17, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,273,657
    Open 42.20
    Bid (Size) 44.04 (100)
    Ask (Size) 45.26 (1,000)
    Prev. Close 42.63
    Today's Range 42.04 - 45.32
    52wk Range 14.62 - 49.70
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Definium Therapeutics Announces New Employee Inducement Grants
    From Definium Therapeutics, Inc.
    Via Business Wire
    News headline image
    Definium Therapeutics’ DT120 Meets Phase III Goals in GAD Study ↗
    Definium Therapeutics (NASDAQ:DFTX) reported positive top-line results from Voyage, its Phase III study evaluating a single 100 mcg dose of DT120 ODT for generalized anxiety disorder, or GAD. The... 
    Via MarketBeat

    Performance

    YTD
    +194.3%
    +194.3%
    1 Month
    +2.2%
    +2.2%
    3 Month
    +121.0%
    +121.0%
    6 Month
    +167.8%
    +167.8%
    1 Year
    +194.3%
    +194.3%

    More News

    Read More
    Wondering what's happening in today's pre-market session? ↗
    Via Chartmill
    News headline image
    Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder
    From Definium Therapeutics, Inc.
    Via Business Wire
    Definium Therapeutics (NASDAQ:DFTX) Slides After Q2 Loss Misses Estimates on Warrant Charge ↗
    Via Chartmill
    News headline image
    Definium Therapeutics Q2 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    News headline image
    Definium Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
    From Definium Therapeutics, Inc.
    Via Business Wire
    News headline image
    A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 Readout
    From USA News Group
    Via GlobeNewswire
    News headline image
    Definium Therapeutics Announces New Employee Inducement Grants
    From Definium Therapeutics, Inc.
    Via Business Wire
    News headline image
    Definium Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026
    From Definium Therapeutics, Inc.
    Via Business Wire
    News headline image
    Definium Therapeutics Announces New Employee Inducement Grants
    From Definium Therapeutics, Inc.
    Via Business Wire
    News headline image
    Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology
    From Definium Therapeutics, Inc.
    Via Business Wire
    News headline image
    New Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD)
    From Definium Therapeutics, Inc.
    Via Business Wire
    News headline image
    Definium Therapeutics Announces New Employee Inducement Grants
    From Definium Therapeutics, Inc.
    Via Business Wire
    News headline image
    Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
    Via FinancialNewsMedia
    News headline image
    Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
    From MarketNewsUpdates.com
    Via GlobeNewswire
    News headline image
    Definium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
    From Definium Therapeutics, Inc.
    Via Business Wire
    News headline image
    Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering
    From Definium Therapeutics, Inc.
    Via Business Wire
    News headline image
    Definium Therapeutics, Inc. Announces Proposed Public Offering
    From Definium Therapeutics, Inc.
    Via Business Wire
    Top movers analysis one hour before the close of the markets on 2026-06-22: top gainers and losers in today's session. ↗
    Via Chartmill
    Which stocks are moving on Monday? ↗
    Via Chartmill
    Monday's session: gap up and gap down stocks ↗
    Via Chartmill
    News headline image
    Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder
    From Definium Therapeutics, Inc.
    Via Business Wire
    News headline image
    Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026
    From Definium Therapeutics, Inc.
    Via Business Wire
    News headline image
    Definium Therapeutics Announces New Employee Inducement Grants
    From Definium Therapeutics, Inc.
    Via Business Wire

    Frequently Asked Questions

    Is Definium Therapeutics, Inc. - Common Shares publicly traded?
    Yes, Definium Therapeutics, Inc. - Common Shares is publicly traded.
    What exchange does Definium Therapeutics, Inc. - Common Shares trade on?
    Definium Therapeutics, Inc. - Common Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for Definium Therapeutics, Inc. - Common Shares?
    The ticker symbol for Definium Therapeutics, Inc. - Common Shares is DFTX on the Nasdaq Stock Market
    What is the current price of Definium Therapeutics, Inc. - Common Shares?
    The current price of Definium Therapeutics, Inc. - Common Shares is 45.26
    When was Definium Therapeutics, Inc. - Common Shares last traded?
    The last trade of Definium Therapeutics, Inc. - Common Shares was at 08/17/26 04:00 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.